H.C. Wainwright & Co.

On Tuesday, H.C. Wainwright & Co. issued a company note on Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) after the company had a positive Phase 3 trial win in oncology, with a survival win in AML of their drug Vyxeos. After the news, analysts at H.C. Wainwright reiterated their Buy rating...

H.C. Wainwright's Andrew S. Fein reiterated a Buy rating on Amarin Corporation plc (ADR) (NASDAQ: AMRN), with a price target of $10. The DMC decision is expected July–August 2016, and Fein believes that the study is likely to be recommended to be continued as planned. However, management...

In a report published Wednesday, H.C. Wainwright analyst Reni Benjamin said that this year’s American Association of Clinical Oncology (ASCO) conference, which was held in Chicago from May 29 to June 2, comprised of presentations that "potentially generate shareholder value for select...

H.C. Wainwright & Co. on Tuesday initiated coverage on Celladon Corp (NASDAQ: CLDN) after impressive clinical trial results for its gene therapy Mydicar. Wainwright rates Celladon as a Buy with a $31 price target. Analyst Ching-Yi Lin wrote, "Thus far, we believe that the clinical trial results...

In a report published Thursday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $6.00 price target on OXiGENE Inc. (NASDAQ: OXGN). In the report, H.C. Wainwright & Co. noted, "We are reiterating our Buy rating and 12-month target price of $6 based on a discounted P/E...

In a report published Tuesday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Oncothyreon (NASDAQ: ONTY) with a Buy rating and $4.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Oncothyreon Inc. with a Buy rating and a 12-month...

In a report published Thursday, H.C. Wainwright & Co. analyst Amit Dayal initiated coverage on Finjan Holdings, Inc. (NASDAQ: FNJN) with a Buy rating and $5.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage on Finjan Holdings, Inc. (FNJN) with a Buy...

In a report published Monday, H.C. Wainwright & Co. analyst Heiko F. Ihle initiated coverage on PolyMet Mining Corp. (USA) (NYSE: PLM) with a Buy rating and $2.10 price target. In the report, H.C. Wainwright & Co. noted, “PolyMet Mining is focused on the permitting and development of its...

In a note released Friday morning, H.C. Wainwright analyst Andrew Fein initiated coverage of Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) with a Buy rating and a $12 price target. Fein's optimistic view for the stock is based on the company's "value driver" TH-302 being in...

In a report published Monday, H.C. Wainwright & Co. analyst Swayampakula Ramakanth initiated coverage on MELA Sciences (NASDAQ: MELA) with a Buy rating and $4.50 price target. In the report, H.C. Wainwright & Co. noted, “MELA Sciences has developed a multi-spectral scanning device, MelaFind...

In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $15.00 price target on Spectrum Pharmaceuticals (NASDAQ: SPPI). In the report, H.C. Wainwright & Co. noted, “We are reiterating our BUY rating for Spectrum Pharmaceuticals and a 12-month...

In a report published Friday, H.C. Wainwright & Co. analyst Reni Benjamin reiterated a Buy rating and $19.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX). In the report, H.C. Wainwright & Co. noted, “We are reiterating our BUY rating on Keryx Pharmaceuticals and maintaining our...

Vertex Pharmaceuticals (NASDAQ: VRTX) reported earnings after the bell on Tuesday, July 29, that beat consensus estimates. Despite the beat, the stock declined in Wednesday's trading action by 3.73 percent. Credit Suisse reiterated a Neutral rating, $94 price target: “VRTX reported non-GAAP EPS...

In a report released Thursday, H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage on AEterna Zentaris (NASDAQ: AEZS) with a Buy rating and a 12-month price target of $3.00 per share. Analysts at H.C. Wainwright favor AEterna for the likelihood of its drug Macrilen passing its FDA...